No abstract

anticoagulation. Follow-up CT abdomen/pelvis three weeks after admission displays significantly improved enhancement pattern throughout the liver with minimal residual heterogeneous enhancement. The patient reports improvement in her abdominal pain during follow-up appointments, and her liver enzymes are trending back to normal levels. She follows up outpatient with hematology/oncology, however her hypercoagulable lab work-up continues to be unremarkable. Discussion: This case demonstrates that portal vein thrombosis may occur following COVID vaccination. The timeline of her developing portal vein thrombosis soon after receiving the COVID vaccination may be suggestive of the vaccine precipitating her condition. This patient did have an additional risk factor of tobacco use. This can be a challenging situation for many clinicians to navigate, as COVID remains a significant threat to patients' health. Patients with hypercoagulable risk factors may benefit from close monitoring for abdominal pain or other symptoms surrounding COVID vaccination.